Drug Trial Radar · NCT05345418
Umbilical Cord-Derived Mesenchymal Stem Cell (VCELL 1) for Male Patients With Sexual Deficiency
Last checked: Nov 19, 2026Latest source record: Jun 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
158
Planned (sponsor's estimate)
Start
Apr 1, 2022
Primary completion
Jun 1, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Vinmec Research Institute of Stem Cell and Gene TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 50 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Sexual functional deficiency affects largely the physical conditions, life and sexual quality of the patients. Hypogonadism affects about 4 to 5 million men in the US, and the incidence increases with age. In our recent phase I clinical trial, we have shown that intravenous adipose - derived MSC administration was safe in female and male patients with hormone deficiency. Post-transplantation sexual satisfaction was observed in all patients enrolled in this study. Testosterone levels in males increased significantly after transplantation and were maintained at high levels for up to 6 months before decreasing again at the 12-month follow-up. The aim of this clinical trial was to assess the safety and effectiveness of allogeneic administration of MSCs in middle-aged people with sexual functional deficiency.
Conditions
- Sexual Dysfunction Male
Interventions
Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual DeficiencyBiological
Patients will receive two administrations at a dose of 1.5 million cells/kg patient bodyweight via the IV route with a 3-month intervening interval. A validated umbilical cord blood mesenchymal stem cells (UC-MSC) line was selected from the Vinmec Tissue Bank and cultured under xeno-free, serum-free and antibiotic-free conditions as previously described. To prepare UC-MSCs for therapy, aliquots of Passage 3 (P3) UC-MSCs will be thawed and cultured to P5 to get approximately 500 million cells and dispensed to 10 million UC-MSCs/ml/vial for cryopreservation. Upon request from the clinical team, aliquots of P5 UC-MSCs will be thawed in a temperature control water bath or incubator on the infusion day. The UC-MSCs will be washed and suspended in Ringer Lactate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The safety of allogenic umbilical cord-derived mesenchymal stem cell administration for the treatment of hormone deficiency in maleTime frame: up to the 12-month period following treatment
- Testosterone levelsTime frame: up to the 12-month period following treatment
- Changes in sexual life quality using Aging Men Symptom (AMS)Time frame: up to the 12-month period following treatment
- Changes in sexual life quality through quantification of International Index of Erectile Function (IIEF)Time frame: up to the 12-month period following treatment
- Changes in sexual life quality through quantification of Sexual Quality of Life Questionnaire (SQoL-M)Time frame: up to the 12-month period following treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vinmec Research Institute of Stem Cell and Gene Technology
Hanoi, Vietnam · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.